Osteonecrosis of the Jaw in Patients with Multiple Myeloma Treated with Bisphosphonates: Definition and Management of the Risk Related to Zoledronic Acid-Reference-Cited by-同舟云学术

Osteonecrosis of the Jaw in Patients with Multiple Myeloma Treated with Bisphosphonates: Definition and Management of the Risk Related to Zoledronic Acid

Published:2008-04 Issue:2 Volume:8 Page:111-116
ISSN:1557-9190
Container-title:Clinical Lymphoma and Myeloma
language:en
Short-container-title:Clinical Lymphoma and Myeloma

Author:

Cafro Anna Maria,Barbarano Luciana,Nosari Anna Maria,D'Avanzo Giovanna,Nichelatti Michele,Bibas Michele,Gaglioti Domenico,Taroni Alberto,Riva Francesco,D'Avanzo Giovanna,Andriani Alessandro

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference38 articles.

1. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo;Hughes;J Bone Miner Res,1995

2. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclastic mediated resorption;Vitté;Endocrinology,1996

3. Inhibition of osteoclast-like cell formation by bisphosphonates in long term cultures of human bone marrow;Hughes;J Clin Invest,1989

4. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy;Sato;J Bone Miner Res,1990

5. MMP inhibition and downregulation by bisphosphonates;Teronen;Ann N Y Acad Sci,1999

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osteonecrosis of the Jaw Associated with Bisphosphonates Infusion for Treatment of Plasma Cell Myeloma—A Retrospective Observational Study of Northern Portuguese Population;Journal of Clinical Medicine;2024-05-02

2. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis;Supportive Care in Cancer;2021-11-05

3. Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis;Journal of Immunotherapy and Precision Oncology;2021-09-30

4. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases;Cancer Chemotherapy and Pharmacology;2021-03-31

5. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases;Supportive Care in Cancer;2021-02-01